Everolimus plus endocrine therapy beyond CDK4/6 inhibitors progression for HR+ /HER2− advanced breast cancer: a real-world evidence cohort-Reference-Cited by-同舟云学术

Everolimus plus endocrine therapy beyond CDK4/6 inhibitors progression for HR+ /HER2− advanced breast cancer: a real-world evidence cohort

Published:2024-05-04 Issue:3 Volume:206 Page:551-559
ISSN:0167-6806
Container-title:Breast Cancer Research and Treatment
language:en
Short-container-title:Breast Cancer Res Treat

Author:

Sánchez-Bayona Rodrigo,Lopez de Sa Alfonso,Jerez Gilarranz Yolanda,Sanchez de Torre Ana,Alva Manuel,Echavarria Isabel,Moreno Fernando,Tolosa Pablo,Herrero Lopez Blanca,de Luna Alicia,Lema Laura,Gamez Casado Salvador,Madariaga Ainhoa,López-Tarruella Sara,Manso Luis,Bueno-Muiño Coralia,Garcia-Saenz Jose A.,Ciruelos Eva,Martin Miguel^ORCID

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s10549-024-07324-8.pdf

Reference39 articles.

1. Malmgren JA, Mayer M, Atwood MK et al (2018) Differential presentation and survival of de novo and recurrent metastatic breast cancer over time: 1990–2010. Breast Cancer Res Treat 167(2):579–590

2. Pan H, Gray R, Braybrooke J et al (2017) 20-Year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years. N Engl J Med 377(19):1836–1846

3. Gennari A, André F, Barrios CH, Cortés J, de Azambuja E, DeMichele A, Dent R, Fenlon D, Gligorov J, Hurvitz SA, Im SA, Krug D, Kunz WG, Loi S, Penault-Llorca F, Ricke J, Robson M, Rugo HS, Saura C, Schmid P, Singer CF, Spanic T, Tolaney SM, Turner NC, Curigliano G, Loibl S, Paluch-Shimon S, Harbeck N, ESMO Guidelines Committee (2021) ESMO clinical practice guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann Oncol 32(12):1475–1495. https://doi.org/10.1016/j.annonc.2021.09.019

4. Turner NC, Ro J, André F et al (2015) Palbociclib in hormone-receptor- positive advanced breast cancer. N Engl J Med 373(3):209–219

5. Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Hart L, Campone M, Petrakova K, Winer EP, Janni W, Conte P, Cameron DA, André F, Arteaga CL, Zarate JP, Chakravartty A, Taran T, Le Gac F, Serra P, O’Shaughnessy J (2022) Overall survival with ribociclib plus letrozole in advanced breast cancer. N Engl J Med 386(10):942–950. https://doi.org/10.1056/NEJMoa2114663

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Rationale for the Initiation, Outcomes, and Characteristics of Chemotherapy Following CDK4/6 Inhibitors in Breast Cancer: A Real-World Cohort Study;Cancers;2024-08-20